CDC Recommendation on Meningitis Vaccine

The AP reports that the U.S. Centers for Disease Control have announced that there is no longer a shortage in the meningitis vaccine, Menactra, manufactured by Sanofi Pasteur. Last year, after the Food and Drug Administration approved Menactra for marketing, the CDC recommended that three age groups — college freshmen, teens entering high school and children aged 11-12 — receive the vaccine. In May 2006, the CDC delisted preteens due to a vaccine shortage. That shortage now has been resolved and the CDC has reinstated its recommendation that children aged 11 – 12 receive the vaccine.